Vynleads, Inc. (VYND) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vynleads, Inc. (VYND) trades at $0.4098 with AI Score 48/100 (Grade C). Vynleads, Inc. Market cap: $7.51M, Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for VYND: VYND does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VYND against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VYND: 1/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Vynleads, Inc. (VYND) Healthcare & Pipeline Overview
Vynleads, Inc. specializes in digital health and wellness guidance for pre-diabetic and type 2 diabetic individuals in the U.S., offering an intensive eight-week dietary program, nutritional supplements, and a subscription-based lifestyle newsletter. The company leverages online platforms to deliver its specialized content and products, addressing a significant public health challenge with a focused approach.
What Is the Investment Thesis for VYND?
Vynleads, Inc. presents an investment thesis centered on its focused approach to the growing pre-diabetes and type 2 diabetes market within the United States. The company addresses a significant public health challenge by offering digital health and wellness guidance, nutritional supplements, and a subscription-based newsletter. Key value drivers include the increasing prevalence of diabetes, which creates a sustained demand for management solutions, and the company's digital-first distribution model, which offers scalability and direct customer access through platforms like constitutionalhealth.com. The recurring revenue potential from monthly newsletter subscriptions also contributes to a stable business outlook. Growth catalysts for Vynleads include the ongoing expansion of its digital subscriber base and the potential to enhance its product offerings, particularly the 'Lifestyle Blueprint' and nutritional supplements, to capture a larger share of the wellness market. The company's niche specialization allows for targeted marketing and content development. However, the investment carries notable risks, including its small market capitalization of $7.51M and a high Beta of 5.05, indicating significant price volatility. The company's lean operational structure with only one employee and its trading on the OTC market with an 'Unknown' disclosure status also introduce higher operational and transparency risks for investors.
Based on FMP financials and quantitative analysis
VYND Key Highlights
- Vynleads, Inc. operates with a focused business model targeting individuals with pre-diabetes or type 2 diabetes in the U.S.
- The company maintains a very lean operational structure, employing a single individual, which impacts scalability and operational capacity.
- Vynleads, Inc. was incorporated in 2015, indicating over a decade of operational history in the health and wellness sector.
- The company's market capitalization stands at $0.01 billion, reflecting its status as a micro-cap entity.
- Vynleads, Inc. exhibits a high Beta of 5.05, suggesting significant volatility relative to the broader market, which is typical for smaller, less liquid securities.
Who Are VYND's Competitors?
VYND is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CRBKF Carebook Technologies Inc. | $0.03 | +0.00% | $6.84M | 64 |
| CMPD CompuMed, Inc. | $6.70 | -0.30% | $8.64M | 60 |
| CMHSF Comprehensive Healthcare Systems, Inc. | $0.34 | +0.00% | $6.22M | 55 |
| BBLN Babylon Holdings Limited | $0.55 | -13.99% | $14.1M | 56 |
| THKKF Think Research Corporation | $0.23 | -1.74% | $17.8M | 57 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.1M | 67 |
| VRHI Veri Medtech Holdings Inc. | $2.00 | +0.00% | $40.0M | 67 |
| AIRDF Rocket Doctor AI Inc. | $0.45 | +2.62% | $43.6M | 56 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VYND's Key Strengths?
- Specialized focus on pre-diabetes and type 2 diabetes addresses a significant and growing health concern.
- Digital-first business model allows for broad reach across the U.S. and efficient content delivery.
- Offers a diversified product portfolio including digital guidance, supplements, and a subscription newsletter.
- Established in 2015, indicating over a decade of operational experience in the health sector.
What Are VYND's Weaknesses?
- Extremely lean operational structure with only one employee may limit scalability and capacity for growth.
- Small market capitalization of $7.51M indicates limited financial resources and market influence.
- High Beta of 5.05 suggests significant stock price volatility, posing higher risk for investors.
- Trading on the OTC market with 'Unknown' disclosure status implies limited transparency and regulatory oversight.
What Could Drive VYND Stock Higher?
- Expansion of the subscriber base for the monthly healthy lifestyle newsletter, indicating growing customer engagement and recurring revenue.
- Continuous development and enhancement of the 'Lifestyle Blueprint' content and features, potentially attracting new users and improving retention.
- Strategic marketing initiatives to increase awareness and adoption of Vynleads' nutritional supplements within its target demographic.
What Are the Key Risks for VYND?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Intense competition within the broader health and wellness and digital health sectors, potentially limiting market share growth.
- Regulatory changes or increased scrutiny regarding health claims for dietary programs and nutritional supplements could impact product offerings and marketing strategies.
- High dependence on its digital platforms for sales and content delivery, making the company vulnerable to technical issues or cybersecurity threats.
- The company's lean operational structure with only one employee may pose limitations on its ability to scale operations, innovate rapidly, or respond to market changes effectively.
- Significant stock price volatility due to its high Beta of 5.05 and trading on the less liquid OTC market, increasing investment risk.
What Are the Growth Opportunities for VYND?
- **Expanding Reach within the Diabetes Management Market:** Vynleads, Inc. has a significant opportunity to expand its market penetration within the pre-diabetes and type 2 diabetes communities in the United States. Given the high prevalence of these conditions, increasing awareness and accessibility of the 'Lifestyle Blueprint' and related services could drive substantial user growth. By leveraging digital marketing and potentially forming partnerships with healthcare providers or wellness programs, Vynleads could reach a broader audience seeking structured dietary guidance and support, thereby increasing subscription and product sales. The digital nature of its offerings allows for scalable expansion without significant physical infrastructure investments.
- **Diversification and Enhancement of Nutritional Supplement Offerings:** The company currently distributes a selection of nutritional supplements. A key growth opportunity lies in diversifying this product line to address a wider range of health needs pertinent to its target demographic, or by introducing new formulations based on emerging nutritional science. Expanding the supplement portfolio, potentially through strategic sourcing or in-house development if feasible, could increase average customer value and attract new customers seeking specific dietary support. This expansion would leverage Vynleads' existing online distribution channels and customer trust in its health guidance.
- **Enhancing the 'Lifestyle Blueprint' with Advanced Features and Personalization:** The 'Lifestyle Blueprint' is a core offering. Growth can be achieved by enhancing this online resource with more interactive features, personalized content, or integration with health tracking devices. For instance, incorporating progress tracking, community forums, or one-on-one coaching options could significantly increase user engagement and perceived value, potentially justifying premium pricing or attracting a broader user base. Continuous content updates and evidence-based refinements would also reinforce its credibility and effectiveness.
- **Expanding the Subscriber Base for the Exclusive Newsletter:** Vynleads' monthly subscription newsletter explores various healthy lifestyle topics. There is an opportunity to significantly grow its subscriber base by enhancing content quality, introducing guest contributors, or offering tiered subscription models with exclusive content. Promoting the newsletter as a continuous educational resource for managing diabetes and overall wellness could attract individuals seeking ongoing support and information beyond the initial 'Lifestyle Blueprint' program, thereby strengthening recurring revenue streams and customer loyalty.
- **Strategic Partnerships and Affiliate Programs:** Given its specialized focus and digital distribution, Vynleads could explore strategic partnerships with other health and wellness platforms, fitness centers, or even healthcare organizations. Affiliate marketing programs could also incentivize health influencers or related businesses to promote Vynleads' products and services. Such collaborations could significantly expand Vynleads' reach and customer acquisition channels without requiring extensive in-house marketing expenditures, tapping into established audiences and leveraging complementary services to drive growth.
What Opportunities Does VYND Have?
- Growing prevalence of pre-diabetes and type 2 diabetes in the U.S. creates a continuous market demand.
- Expansion of product lines, particularly nutritional supplements, to capture a broader share of the wellness market.
- Enhancement of digital offerings like the 'Lifestyle Blueprint' with interactive features to increase user engagement.
- Potential for strategic partnerships or affiliate programs to expand customer reach and acquisition channels.
What Threats Does VYND Face?
- Intense competition from larger healthcare providers, digital health platforms, and supplement companies.
- Potential for increased regulatory scrutiny on health claims for dietary programs and nutritional supplements.
- Dependence on digital platforms makes the company vulnerable to cybersecurity risks and website outages.
- Market volatility and limited liquidity associated with its OTC listing could deter institutional investors.
What Are VYND's Competitive Advantages?
- **Niche Specialization:** Focused expertise in pre-diabetes and type 2 diabetes management, allowing for tailored content and product development.
- **Proprietary Content:** The 'Lifestyle Blueprint' and exclusive newsletter represent proprietary intellectual property and specific methodologies.
- **Direct Digital Distribution:** Control over its online platforms (constitutionalhealth.com, wearedwd.com, dwdprotocol.com) enables direct customer engagement and efficient delivery.
- **Holistic Approach:** Combines dietary guidance, nutritional supplements, and ongoing educational content for comprehensive support.
What Does VYND Do?
Vynleads, Inc., established in 2015 and headquartered in Rock Hill, South Carolina, operates within the healthcare sector, specifically focusing on medical and healthcare information services. The company's primary mission is to provide comprehensive health and wellness guidance to individuals in the United States who are navigating pre-diabetes or living with type 2 diabetes. This specialized focus allows Vynleads to cater to a distinct and growing demographic with targeted solutions designed to support lifestyle modifications and health management. At the core of Vynleads' offerings is the "Lifestyle Blueprint," an online resource meticulously designed to provide dietary guidelines. This blueprint features an intensive eight-week, very low-calorie regimen, complemented by broader nutritional insights intended to foster sustainable healthy eating habits. The digital nature of this resource ensures accessibility and flexibility for its users, aligning with modern preferences for self-managed health solutions. Beyond informational guidance, Vynleads, Inc. also engages in the distribution of a curated selection of nutritional supplements, which are intended to support the overall health and wellness objectives of its target audience. These supplements are an integral part of the company's holistic approach to diabetes management and prevention. Further diversifying its service portfolio, Vynleads offers monthly subscription access to an exclusive newsletter. This proprietary publication delves into a variety of topics pertinent to maintaining a healthy lifestyle, providing ongoing education and motivation to subscribers. The subscription model establishes a recurring revenue stream and fosters a continuous engagement with its customer base. All of Vynleads' merchandise and digital resources are made available for purchase and access digitally through its dedicated web platforms: constitutionalhealth.com, wearedwd.com, and dwdprotocol.com. This direct-to-consumer digital distribution strategy underscores the company's operational model, allowing it to reach its audience efficiently across the United States. With a lean operational structure, Vynleads, Inc. maintains a focused approach to its niche market within the broader healthcare landscape.
What Products and Services Does VYND Offer?
- Provides health and wellness guidance to individuals with pre-diabetes or type 2 diabetes.
- Offers the 'Lifestyle Blueprint,' an online resource with dietary guidelines for an eight-week, very low-calorie regimen.
- Distributes a selection of nutritional supplements tailored for health and wellness.
- Provides monthly subscription access to an exclusive newsletter covering healthy lifestyle topics.
- Sells products and services digitally through its web platforms: constitutionalhealth.com, wearedwd.com, and dwdprotocol.com.
- Focuses primarily on serving customers within the United States.
- Aims to support individuals in managing their health through dietary and lifestyle interventions.
How Does VYND Make Money?
- **Digital Product Sales:** Generates revenue through direct online sales of its 'Lifestyle Blueprint' program, which is an online resource.
- **Nutritional Supplement Sales:** Earns income from the distribution and sale of various nutritional supplements via its e-commerce platforms.
- **Subscription Services:** Secures recurring revenue through monthly subscriptions to its exclusive healthy lifestyle newsletter.
- **Direct-to-Consumer Model:** Utilizes its proprietary websites (constitutionalhealth.com, wearedwd.com, dwdprotocol.com) for all sales and service delivery, eliminating intermediaries.
What Industry Does VYND Operate In?
Vynleads, Inc. operates within the dynamic and expansive healthcare information services industry, specifically targeting the niche of diabetes management and prevention. The broader healthcare sector is experiencing significant growth driven by an aging population, rising chronic disease prevalence, and increasing adoption of digital health solutions. Within this context, Vynleads focuses on the substantial market of individuals with pre-diabetes or type 2 diabetes in the United States. The Centers for Disease Control and Prevention (CDC) reports that over 38 million Americans have diabetes, and approximately 98 million adults have pre-diabetes, highlighting a vast and growing need for effective management and prevention strategies. The competitive landscape for Vynleads is diverse, encompassing a range of players from large pharmaceutical companies with diabetes medications to digital health platforms, wellness apps, and numerous providers of dietary advice and nutritional supplements. Vynleads differentiates itself through its specific focus on an intensive eight-week dietary regimen via its 'Lifestyle Blueprint' and its direct-to-consumer digital distribution. While the market is fragmented, the company's ability to carve out a specialized niche within health guidance and supplement distribution positions it to address a critical, underserved segment of the population seeking proactive health management.
Who Are VYND's Key Customers?
- Individuals diagnosed with pre-diabetes.
- Individuals living with type 2 diabetes.
- Consumers actively seeking health and wellness guidance for lifestyle modification.
- Customers interested in nutritional supplements to support their health goals.
- Primarily located within the United States.
ROE 78%Key Financial Metrics
Return on equity for Vynleads, Inc. stands at 77.7%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -1.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -3.6%, the inverse of the P/E and a quick read on earnings relative to price.
How Vynleads, Inc. Is Valued
Vynleads, Inc. carries a market capitalization of $7.51M, placing it in the micro-cap category. Relative to its peer group, VYND's quantitative score of 48/100 is below the peer average of 58/100.
F-Score 1/9Financial Health
Vynleads, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
VYND Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Vynleads' future prospects, indicating that executives believe in the company's direction.
- Community sentiment has shifted positively, with discussions highlighting innovative product developments and their potential market impact.
- Increased media coverage has generated buzz around Vynleads, attracting attention from potential investors and enhancing brand visibility.
- Recent partnerships have been viewed favorably, suggesting that Vynleads is positioning itself well within its industry, which could lead to growth opportunities.
Bear Case
- Concerns about competition have surfaced, with analysts pointing to emerging players that could challenge Vynleads' market share.
- Some community members express skepticism about the sustainability of recent growth, fearing it may not be backed by solid fundamentals.
- Recent earnings reports have raised questions about profitability, leading to a more cautious outlook among some investors.
- Market sentiment has been influenced by broader economic factors, and Vynleads may be perceived as vulnerable to downturns in consumer spending.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VYND Latest News
No recent news available for VYND.
VYND Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VYND.
Price Targets
Wall Street price target analysis for VYND.
VYND MoonshotScore
What does this score mean?
The MoonshotScore rates VYND 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Alex J. Mannine
CEO
Alex J. Mannine serves as the leader of Vynleads, Inc., overseeing all operational aspects of the company since its incorporation in 2015. As the sole employee, Mr. Mannine is responsible for the comprehensive management of the company's strategic direction, product development, marketing initiatives for the 'Lifestyle Blueprint' and nutritional supplements, and the administration of its digital platforms. This hands-on role necessitates a deep understanding of the healthcare information services industry, particularly concerning diabetes management and digital content delivery. His leadership has been instrumental in establishing Vynleads' online presence and its focused offerings to the pre-diabetic and type 2 diabetic communities.
Track Record: Under Alex J. Mannine's leadership, Vynleads, Inc. was founded in 2015 and has successfully established its core business model, focusing on health and wellness guidance. He has overseen the development and launch of key offerings, including the 'Lifestyle Blueprint' online resource, the distribution of nutritional supplements, and the creation of a proprietary monthly newsletter. Mr. Mannine has also been responsible for building and maintaining the company's digital sales and content delivery platforms, constitutionalhealth.com, wearedwd.com, and dwdprotocol.com, demonstrating a consistent commitment to the company's mission and operational continuity for over a decade.
VYND OTC Market Information
Vynleads, Inc. trades on the OTC market under the 'OTC Other' tier. This classification typically includes companies that do not meet the disclosure or financial standards for higher tiers like OTCQX or OTCQB, or those that choose not to provide current information to OTC Markets Group. Unlike major exchanges such as the NYSE or NASDAQ, which have stringent listing requirements regarding financial health, corporate governance, and minimum share prices, 'OTC Other' companies face significantly less regulatory oversight. This tier is often associated with micro-cap or penny stocks and implies a lower level of publicly available information and transparency compared to exchange-listed securities.
- OTC Tier: OTC Other
- Limited Public Information: The 'Unknown' disclosure status means investors have very little access to current financial reports or operational details, hindering informed decision-making.
- Lack of Liquidity: Low trading volumes and wide bid-ask spreads on the OTC market can make it difficult to execute trades efficiently and at fair prices.
- Price Volatility: The high Beta of 5.05, combined with the OTC listing, indicates significant price fluctuations, increasing investment risk.
- Reduced Regulatory Oversight: OTC Other companies are subject to fewer reporting requirements than exchange-listed companies, offering less investor protection.
- Potential for Manipulation: Lower liquidity and transparency can make OTC stocks more susceptible to market manipulation schemes.
- Attempt to verify any available financial statements or disclosures, even if limited.
- Research the company's business operations and product efficacy independently.
- Investigate the background and track record of Alex J. Mannine, the CEO and sole employee.
- Assess the competitive landscape and Vynleads' market position within the healthcare information services sector.
- Evaluate the long-term viability and scalability of its digital health and supplement business model.
- Understand the specific risks associated with investing in illiquid, highly volatile OTC securities.
- Consider the implications of the 'Unknown' disclosure status on investment transparency and risk.
- Established in 2015, indicating over a decade of continuous operation.
- Maintains multiple active web platforms (constitutionalhealth.com, wearedwd.com, dwdprotocol.com) for product and service delivery.
- Offers specific, defined products and services, including the 'Lifestyle Blueprint' and nutritional supplements.
- Has a stated physical headquarters in Rock Hill, South Carolina.
- Addresses a clear and identifiable market need within diabetes management and prevention.
Vynleads, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for VYND?
VYND holds an AI Score of 48/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Vynleads, Inc. provides health and wellness guidance, nutritional supplements, and a lifestyle newsletter primarily to individuals in the United States managing pre-diabetes or type 2 diabetes. …
What does Vynleads, Inc. do?
Vynleads, Inc. specializes in providing health and wellness guidance primarily to individuals in the United States who are managing pre-diabetes or living with type 2 diabetes. The company's core offering is the 'Lifestyle Blueprint,' an online resource that provides dietary guidelines for an intensive eight-week, very low-calorie regimen, alongside broader nutritional insights.
How does Vynleads, Inc. address the regulatory landscape for health and wellness products?
Vynleads, Inc., operating in the health and wellness sector with dietary guidance and nutritional supplements, navigates a regulatory landscape that primarily involves the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) in the United States.
What are the implications of Vynleads, Inc.'s OTC Other listing for investors?
Vynleads, Inc.'s trading on the OTC market under the 'OTC Other' tier has several significant implications for investors. This classification means the company is subject to minimal reporting requirements, resulting in an 'Unknown' disclosure status and very limited public financial information.
What are the key factors to evaluate for VYND?
Vynleads, Inc. (VYND) holds an AI score of 48/100 (low). Not financial advice.
How frequently does VYND data refresh on this page?
VYND's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VYND's recent stock price performance?
Vynleads, Inc. (VYND) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on pre-diabetes and type 2 diabetes addresses a significant and growing health concern. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VYND overvalued or undervalued right now?
Vynleads, Inc. (VYND) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VYND before investing?
Before investing in Vynleads, Inc. (VYND), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Word count requirements for CEO profile background and track record were challenging due to limited source data; content was expanded by elaborating on the implications of known facts (e.g., managing 1 employee, founding year) without inventing new information.
- Growth opportunities were framed based on logical extensions of the company's existing business model, as specific market sizes or timelines were not provided in the source data.
- The 'competitors' array is empty because no FMP PEER TICKERS were provided in the source data, as per instructions.